



Funded by
the European Union



InnoThyroGen

SURVEY RESULTS

228

PATIENTS SHARED THEIR EXPERIENCE

Thank you to everyone who took
the time to share their experience



228 RESPONSES

Individual voices that help us
better understand
the patient journey.



46 CITIES & TOWNS

Survey participants come from
46 cities and towns across Serbia.



PATIENTS ACROSS SERBIA

Together we are building better
understanding, support and a
patient-centred healthcare system.

Results are based on the responses of 228 participants in the survey "The Patient Journey with Thyroid Diseases – Experiences, Challenges and Needs", conducted within the Horizon Europe project InnoThyroGen.



Funded by
the European Union



InnoThyroGen

ACCESS TO A SPECIALIST

HOW EASY IS IT TO ACCESS A SPECIALIST?

66.7% of respondents said it was moderately or very difficult for them to get a specialist appointment



- Very easy 33.3%
- Moderately difficult 37.3%
- Very difficult 29.4%



The first challenge is often not the diagnosis, but accessing medical care



A timely examination is key to diagnosis and treatment



Access to specialists remains one of the key issues for patients



Funded by
the European Union




InnoThyroGen

INFORMATION

IS INFORMATION ON PREVENTION AVAILABLE TO PATIENTS?

69.7% of respondents feel they do not receive enough information on the prevention of thyroid diseases through the healthcare system



● No	69.7%
● Partially	28.1%
● Yes	2.2%



Quality information enables earlier recognition of symptoms



Timely information helps making treatment decisions



The results point to a need for stronger education and more accessible information



Funded by
the European Union



InnoThyroGen

PERSONALISED MEDICINE

PATIENTS WANT TREATMENT TAILORED TO THEIR NEEDS

77.2% of respondents believe
that additional testing
can help determine
the optimal
treatment



● Very important	77.2%
● Important	18.4%
● Not sure	4.4%



Additional testing can help
choosing the optimal therapy



Treatment should be tailored
to individual needs



Patients want to be active
participants in their treatment.





Funded by
the European Union



InnoThyroGen

GENETIC TESTING

HIGH INTEREST IN GENETIC TESTING

68% of respondents
would be interested in
taking a genetic test
to assess their risk
of thyroid diseases.



● Yes	68%
● Not sure	30.3%
● No	1.7%





Funded by
the European Union



InnoThyroGen

PATIENT INSIGHTS

WHAT HAVE WE LEARNED FROM 228 PATIENTS?

*Thank you to all
survey participants!*



More accessible healthcare



More information on prevention



Greater patient involvement



Individually tailored treatment

